5-溴-2-肼基苯甲酸 | 177192-82-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 5-溴-2-肼基苯甲酸
• 英文名称: 5-Bromo-2-hydrazinylbenzoic acid
• 英文别名: 5-Bromo-2-hydrazinobenzoic acid
• CAS: 177192-82-4
• 化学式: C₇H₇BrN₂O₂
• 分子量: 231.049
• InChiKey: GVRISWMOHPFEDG-UHFFFAOYSA-N

物化性质

• 沸点：
  380.0±37.0 °C(Predicted)
• 密度：
  1.851±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  75.4
• 氢给体数：
  3
• 氢受体数：
  4

安全信息

• 海关编码：
  2928000090

反应信息

• 作为反应物：
  描述：

  5-溴-2-肼基苯甲酸 在 ammonium hydroxide 、 四(三苯基膦)钯 、 水 、 sodium carbonate 、 1-羟基苯并三唑 、 1,2-二氯乙烷 、 2,3-二氯-5,6-二氰基-1,4-苯醌 、 sodium hydroxide 作用下， 以 四氢呋喃 、 甲醇 、 二氯甲烷 、 水 、 丙酮 、 甲苯 为溶剂， 生成 3-(3-fluoro-4-methoxyphenyl)-7-(4-morpholinylcarbonyl)-9H-carbazole-1-carboxamide
  参考文献：
  名称：

  9H-Carbazole-1-carboxamides as potent and selective JAK2 inhibitors

  摘要：

  The discovery, synthesis, and characterization of 9H-carbazole-1-carboxamides as potent and selective ATP-competitive inhibitors of Janus kinase 2 (JAK2) are discussed. Optimization for JAK family selectivity led to compounds 14 and 21, with greater than 45-fold selectivity for JAK2 over all other members of the JAK kinase family. (C) 2015 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2015.04.101
• 作为产物：
  描述：

  2-氨基-5-溴苯甲酸 在 盐酸 、 tin(ll) chloride 、 sodium nitrite 作用下， 以89%的产率得到5-溴-2-肼基苯甲酸
  参考文献：
  名称：

  9H-Carbazole-1-carboxamides as potent and selective JAK2 inhibitors

  摘要：

  The discovery, synthesis, and characterization of 9H-carbazole-1-carboxamides as potent and selective ATP-competitive inhibitors of Janus kinase 2 (JAK2) are discussed. Optimization for JAK family selectivity led to compounds 14 and 21, with greater than 45-fold selectivity for JAK2 over all other members of the JAK kinase family. (C) 2015 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2015.04.101

文献信息

• Matrix metalloproteinase inhibitors
  申请人：——

  公开号：US20030078276A1

  公开（公告）日：2003-04-24

  Compounds are provided that bind allosterically to the catalytic domain of MMP-13 and comprise a hydrophobic group, first and second hydrogen bond acceptors and at least one, and preferably both, of a third hydrogen bond acceptor and a second hydrophobic group. Cartesian coordinates for centroids of the above features are defined in the specification. When the ligand binds to MMP-13, the first, second and third (when present) hydrogen bond acceptors bond respectively with Thr245, Thr 247 and Met 253, the first hydrophobic group locates within the S1′ channel of MMP-13 and the second hydrophobic group (when present) is relatively open to solvent. The compounds specifically inhibit the matrix metalloproteinase-13 enzyme and thus are useful for treating diseases resulting from tissue breakdown, such as heart disease, multiple sclerosis, arthritis, atherosclerosis, and osteoporosis.

  提供了一些与MMP-13的催化结构域发生变构结合的化合物，包括一个疏水基团，第一和第二氢键受体，以及至少一个，最好是两个，第三氢键受体和第二疏水基团。上述特征的质心的笛卡尔坐标在说明书中定义。当配体与MMP-13结合时，第一、第二和第三（存在时）氢键受体分别与Thr245、Thr247和Met253结合，第一个疏水基团位于MMP-13的S1'通道内，第二疏水基团（存在时）相对于溶剂是开放的。这些化合物特异性地抑制基质金属蛋白酶-13酶，因此可用于治疗由组织分解引起的疾病，如心脏病、多发性硬化症、关节炎、动脉粥样硬化和骨质疏松症。
• [EN] SUBSTITUTED PYRAZOLOQUINAZOLINONES AND PYRROLOQUINAZOLINONES AS ALLOSTERIC MODULATORS OF GROUP IIMETABOTROPIC GLUTAMATE RECEPTORS<br/>[FR] PYRAZOLOQUINAZOLINONES ET PYRROLOQUINAZOLINONES SUBSTITUÉES EN TANT QUE MODULATEURS ALLOSTÉRIQUES DES RÉCEPTEURS MÉTABOTROPIQUES DU GLUTAMATE DU GROUPE II
  申请人：DOMAIN THERAPEUTICS

  公开号：WO2016046404A1

  公开（公告）日：2016-03-31

  The present invention provides pyrazoloquinazolinone and pyrroloquinazolinone derivatives of the general formula (I) and pharmaceutical compositions containing them. Moreover, the compounds of formula (I) and the compositions containing them are provided for use in the treatment and/or prophylaxis of conditions associated with altered glutamatergic signalling and/or functions, and/or conditions which can be affected by alteration of glutamate level or signalling in mammals. These pyrazoloquinazolinone and pyrroloquinazolinone derivatives of the general formula (I) can act as modulators of nervous system receptors sensitive to glutamate, in particular as modulators of metabotropic glutamate receptors (mGlu Rs), which makes them particularly suitable for the treatment and/or prophylaxis of acute and chronic neurological and/or psychiatric disorders.

  本发明提供了通式(I)的吡唑并喹唑啉酮和吡咯并喹唑啉酮衍生物以及含有它们的药物组合物。此外，式(I)的化合物及其组合物被提供用于治疗和/或预防与谷氨酸能信号传导和/或功能改变相关的病症，以及可以通过改变哺乳动物中的谷氨酸水平或信号传导而受影响的病症。这些通式(I)的吡唑并喹唑啉酮和吡咯并喹唑啉酮衍生物可以作为神经系统中对谷氨酸敏感的受体调节剂，特别是作为代谢型谷氨酸受体(mGluRs)的调节剂，这使得它们特别适合用于治疗和/或预防急性和慢性神经和/或精神疾病。
• Triazolo compounds as MMP inhibitors
  申请人：——

  公开号：US20020151558A1

  公开（公告）日：2002-10-17

  A compound selected from those of formula (I): 1 in which: W represents N or C—R 1 ; in which R 1 is as defined in the description, X represents N or C—R 2 in which R 2 is as defined in the description, Y represents a group selected from oxygen, sulfur, —NH, and —Nalkyl, Z represents a group selected from oxygen, sulphur, —NR 8 in which R 8 is as defined in the description, and optionally carbon depending the definition of Y, n is an integer from 0 to 8 inclusive, Z 1 represents a group —CR 9 R 10 wherein R 9 and R 10 , are as defined in the description, which group contains optionally multiple bonds or heteroatomes, A represents a cyclic group, m is an integer from 0 to 7 inclusive, the group(s) R 4 is (are) as defined in the description, R 3 represents a group selected from hydrogen, alkyl, alkenyl, alkynyl, and the group of formula: 2 in which p, Z 2 , B, q, and R 13 are as defined in the description, optionally, its racemic forms, isomers thereof, N-oxydes thereof, and its the pharmaceutically acceptable salts thereof, and medicinal products containing the same are useful as specific inhibitors of type-13 matrix mettaloprotease.

  从式（I）中选择的化合物：其中：W代表N或C—R1；其中R1如说明中所定义，X代表N或C—R2，其中R2如说明中所定义，Y代表从氧、硫、—NH和—N烷基中选择的基团，Z代表从氧、硫、—NR8中选择的基团，其中R8如说明中所定义，并根据Y的定义可选碳，n为0至8的整数（含0和8），Z1代表一个基团—CR9R10，其中R9和R10如说明中所定义，该基团可选地包含多个键或杂原子，A代表一个环状基团，m为0至7的整数（含0和7），基团R4如说明中所定义，R3代表从氢、烷基、烯基、炔基和式（2）所示的基团中选择的基团，其中p、Z2、B、q和R13如说明中所定义，可选地包括其外消旋体、同分异构体、N-氧化物及其药学上可接受的盐，以及含有其的药物制剂，作为第13型基质金属蛋白酶的特异性抑制剂是有用的。
• Method of determining potential allosterically-binding matrix metalloproteinase inhibitors
  申请人：Andrianjara Charles

  公开号：US20050004126A1

  公开（公告）日：2005-01-06

  Compounds are provided that bind allosterically to the catalytic domain of MMP-13 and comprise a hydrophobic group, first and second hydrogen bond acceptors and at least one, and preferably both, of a third hydrogen bond acceptor and a second hydrophobic group. Cartesian coordinates for centroids of the above features are defined in the specification. When the ligand binds to MMP-13, the first, second and third (when present) hydrogen bond acceptors bond respectively with Thr245, Thr 247 and Met 253, the first hydrophobic group locates within the S1′ channel of MMP-13 and the second hydrophobic group (when present) is relatively open to solvent. The compounds specifically inhibit the matrix metalloproteinase-13 enzyme and thus are useful for treating diseases resulting from tissue breakdown, such as heart disease, multiple sclerosis, arthritis, atherosclerosis, and osteoporosis.

  提供了一种与MMP-13催化域发生变构作用的化合物，其中包括一个疏水基团、第一和第二氢键受体以及至少一个第三氢键受体和第二个疏水基团，最好是两者都有。上述特征的笛卡尔坐标在说明书中有定义。当配体与MMP-13结合时，第一、第二和第三（存在时）氢键受体分别与Thr245、Thr 247和Met 253结合，第一疏水基团位于MMP-13的S1'通道内，第二疏水基团（存在时）相对于溶剂较为开放。这些化合物特异性地抑制了基质金属蛋白酶-13酶，因此可用于治疗由组织分解引起的疾病，如心脏病、多发性硬化症、关节炎、动脉粥样硬化和骨质疏松症。
• Cyclic compounds containing zinc binding groups as matrix metalloproteinase inhibitors
  申请人：——

  公开号：US20040063673A1

  公开（公告）日：2004-04-01

  This invention provides compounds defined by Formula I Z—L—R 1 —Q—D—(V 1 ) m —R 2 I or a pharmaceutically acceptable salt thereof, wherein Z, L, R 1 , Q, D, V 1 , m, and R 2 are as defined in the specification. The invention also provides pharmaceutical compositions comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof, as defined in the specification, together with a pharmaceutically acceptable carrier, diluent, or excipient. The invention also provides methods of inhibiting an MMP-13 enzyme in an animal, comprising administering to the animal a compound of Formula I, or a pharmaceutically acceptable salt thereof. The invention also provides methods of treating a disease mediated by an MMP-13 enzyme in a patient, comprising administering to the patient a compound of Formula I, or a pharmaceutically acceptable salt thereof, either alone or in a pharmaceutical composition. The invention also provides methods of treating diseases such as heart disease, multiple sclerosis, osteo- and rheumatoid arthritis, arthritis other than osteo- or rheumatoid arthritis, cardiac insufficiency, inflammatory bowel disease, heart failure, age-related macular degeneration, chronic obstructive pulmonary disease, asthma, periodontal diseases, psoriasis, atherosclerosis, and osteoporosis in a patient, comprising administering to the patient a compound of Formula I, or a pharmaceutically acceptable salt thereof, either alone or in a pharmaceutical composition. The invention also provides combinations, comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof, together with another pharmaceutically active component as described in the specification.

  本发明提供了由式子IZ—L—R1—Q—D—（V1）m—R2或其药学上可接受的盐所定义的化合物，其中Z，L，R1，Q，D，V1，m和R2在规范中有定义。本发明还提供了制药组合物，包括由规范中定义的式子I或其药学上可接受的盐所定义的化合物，以及药学上可接受的载体、稀释剂或赋形剂。本发明还提供了抑制动物中MMP-13酶的方法，包括向动物投与式子I或其药学上可接受的盐所定义的化合物。本发明还提供了治疗患有由MMP-13酶介导的疾病的患者的方法，包括向患者投与式子I或其药学上可接受的盐所定义的化合物，单独使用或在制药组合物中使用。本发明还提供了治疗心脏病、多发性硬化症、骨关节炎和类风湿性关节炎、非骨关节炎或类风湿性关节炎的关节炎、心力衰竭、炎症性肠病、老年性黄斑变性、慢性阻塞性肺疾病、哮喘、牙周疾病、银屑病、动脉硬化和骨质疏松症的患者的方法，包括向患者投与式子I或其药学上可接受的盐所定义的化合物，单独使用或在制药组合物中使用。本发明还提供了由式子I或其药学上可接受的盐所定义的化合物与规范中描述的另一种药物活性成分的组合。